Abstract
IntroductionPrevious studies suggested that estrogen receptor alpha (ERα) plays an important role in the chemoresistance of breast cancers. However, large random trials failed to demonstrate any benefit of the concurrent estrogen antagonist tamoxifen on the chemotherapy efficacy. Thus, in the present study, the importance of the role of ERα in the chemoresistance of breast cancer cells was investigated.MethodsThe ERα-transfected Bcap37 cells and natural ERα-positive T47D breast cancer cells were treated using chemotherapeutic agents with or without 17-beta estradiol (E2) pretreatment. Their viabilities were assessed using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assays. The dead cell rates were determined using propidium iodide dye exclusion tests, and the expression levels of Bcl-2 and Bax were detected through Western blot analysis. The effects of E2 on the growth of breast cancer cells were also determined via cell growth curve and cell cycle analysis.ResultsERα activation by E2 increased the sensitivity of natural ERα-positive T47D breast cancer cells to chemotherapeutic agents. However, the increase in ERα expression in ERα-negative Bcap37 breast cancer cells also significantly increased their resistance. These phenomena cannot be explained by asserting that ERα mediated the chemoresistance of breast cancer cells by regulating the expression of Bcl-2 and Bax. Our findings show that ERα activation upregulated the expression of Bcl-2 in natural ERα-positive T47D breast cancer cells, whereas ERα activation by E2 downregulated and upregulated the Bcl-2 and Bax expression levels, respectively, in ERα-transfected Bcap37 cells. This phenomenon was due to the influence of ERα on the growth of breast cancer cells. Specifically, ERα activation enhanced the growth of natural ERα-positive breast cancer cells and thus increased their sensitivity to chemotherapeutic agents. However, ERα activation also inhibited the growth of ERα-transfected Bcap37 cells and increased the resistance of cancer cells to chemotherapeutic agents. Chemoresistance of ERα-transfected Bcap37 cells was only due to the specific growth inhibition by E2, which is not applicable to common ERα-positive breast cancer cells.ConclusionsAlthough ERα was associated with chemoresistance of breast cancers, ERα itself did not mediate this resistance process.
Highlights
Previous studies suggested that estrogen receptor alpha (ERα) plays an important role in the chemoresistance of breast cancers
Activation of ERα by 17-βestradiol (E2) increased the sensibility of ERα-positive T47D cells to chemotherapeutic agents and fulvestant reversed the effect of 17-beta estradiol (E2) 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assays were performed to determine the viability of T47D cells treated with four different chemotherapeutic agents with or without the pretreatment of E2
We found that pretreatment with 2 uM fulvestrant completely reversed E2-induced sensitivity to chemotherapeutic agents (p < 0.05)
Summary
Previous studies suggested that estrogen receptor alpha (ERα) plays an important role in the chemoresistance of breast cancers. In vitro studies have shown that ERα plays an important role in determining the sensitivity of breast cancer cells to chemotherapeutic agents [2,10,11,12,13,14]. ERα-positive breast cancer grows more slowly than an ERα-negative one [21] This gives rise to the question “Is it tumor growth rate (and not ERα expression), which determines the chemosensitivity of breast cancer?” To understand whether or not ERα mediates drug resistance to chemotherapy in breast cancer, an in vitro study was performed by us to determine the relationship between ERα and drug resistance to chemotherapeutic agents in breast cancer cells
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Experimental & Clinical Cancer Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.